Pursuit Vascular Announces Patent Notice of Allowance for its ClearGuard HD Antimicrobial Barrier Caps
- Further strengthens patent portfolio
MAPLE GROVE, Minn., Nov. 27, 2018 /PRNewswire/ -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application for the company's ClearGuard HD caps. Several additional US and international patent applications are pending.
This is the 8th US patent to be issued to Pursuit Vascular for inventions related to the ClearGuard platform technology.
The ClearGuard HD cap is the only device cleared for sale in the U.S. that kills infection-causing bacteria inside a hemodialysis catheter hub. Data from the National Healthcare Safety Network (NHSN) published in 2017 reported 30,000 bloodstream infections (BSIs) in outpatient hemodialysis centers in the United States. BSI is the leading cause of hospitalizations and the second leading cause of death in hemodialysis patients, with catheters causing 70% of BSIs.
Featured in major prospective, randomized controlled trials, patients treated using ClearGuard HD caps showed a significant reduction in bloodstream infections when compared to commonly used caps and connectors. In total, these studies included more than 4,000 catheter patients in 80 dialysis centers and were published in industry-leading journals.
"We are pleased to have received this latest patent, which expands the ClearGuard intellectual property portfolio," said Bob Ziebol, Sr. Vice President of R&D for Pursuit Vascular. "It further protects our platform technology underlying the ClearGuard HD cap and is an indicator of our leadership and dominant position we expect to achieve worldwide."
About the ClearGuard HD Antimicrobial Barrier Cap
The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter hub. The caps are simple to use and clinically shown to reduce central line-associated bloodstream infection. This simple, yet revolutionary single-use device is protected by 8 issued U.S. patents, and several other U.S. patents pending. Foreign patents issued and pending. For more information, visit www.clearguardhd.com.
About Pursuit Vascular
Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. (www.pursuitvascular.com) is developing a family of innovative products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the costs of health care.
Connect with us at www.pursuitvascular.com and on Twitter at @ClearGuardHD.
SOURCE Pursuit Vascular
Share this article